For the Inventor, By the Inventor

Enter assignee name

Sandy, UT, United States of America

Signpath Pharma, Inc.

USPTO Granted Patents = 25

% Expired Patents = 4.0

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 172

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

Lawrence Helson (19 out of 22 patents)

Annie Bouchard (10 out of 11 patents)

George M Shopp (5 out of 7 patents)

4. Daniel Emil Levy (4 out of 16 patents)

5. Saravanan Kappusamy (4 out of 4 patents)

6. John Kallikat Augustine (4 out of 4 patents)

7. Muhammed Majeed (3 out of 117 patents)

8. James D McChesney (3 out of 58 patents)

9. Peter P Sordillo (3 out of 3 patents)

10. Stephen W Burgess (2 out of 16 patents)

11. Razelle Kurzrock (2 out of 5 patents)

12. Lan Li (2 out of 5 patents)

13. Kapil Mehta (2 out of 16 patents)

14. Bharat Bhushan Aggarawal (2 out of 3 patents)

15. Walter Allen Shaw (2 out of 18 patents)

Core Competencies:

Cardioprotective Lipid

Liposomal Mitigation

Dosing Regimens

Cytokine Storm

QT Prolongation

Channelopathies

Curcumin

Phosphodiester Lipids

Glioblastoma Treatment

Intravenous Infusion

Pharmacokinetics

25 patents: Sort by Forward Citations

1. 12617809 - Cardioprotective lipid and method of use (2026-05-05),

2. 12551436 - Dosing regimens for treatment of proliferative disorders (2026-02-17),

3. 12004868 - Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel (2024-06-11),

4. 11813356 - Dosing regimens for treatment of proliferative disorders (2023-11-14),

5. 11806401 - Prevention of drug-induced atrio-ventricular block (2023-11-07),

6. 11746119 - Cardiopathy-reducing phosphodiester lipids (2023-09-05),

7. 11643424 - Cardiopathy-reducing phosphodiester lipids (2023-05-09),

8. 10975111 - Cardiopathy-reducing phosphodiester lipids (2021-04-13),

9. 10739353 - Suppression of cytokine release and cytokine storm (2020-08-11),

10. 10617639 - Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current (2020-04-14),

11. 10532045 - Liposomal mitigation of drug-induced inhibition of the cardiac Ichannel (2020-01-14),

12. 10485768 - Treatment for glioblastoma (2019-11-26),

13. 10449193 - Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies (2019-10-22),

14. 10357458 - Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current (2019-07-23),

15. 10258691 - Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies (2019-04-16),

Company Overview

Signpath Pharma, Inc. is a biopharmaceutical company based in Sandy, Utah, focused on the development of innovative therapies for various medical conditions. The organization specializes in advanced drug delivery systems and is dedicated to enhancing treatment efficacy through its proprietary technologies. Signpath Pharma aims to address unmet medical needs by leveraging its expertise in pharmaceutical formulation and development, contributing to improved patient outcomes in the healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

25 Patents

#4 in Sandy, UT

#157 in Utah

#13,350 in US

#25,681 in the World

Sandy, UT, United States of America

Signpath Pharma, Inc.

Forward Citations = 172

23 inventors:

Lawrence Helson (19 out of 22 patents)

Annie Bouchard (10 out of 11 patents)

George M Shopp (5 out of 7 patents)

4. Daniel Emil Levy (4 out of 16 patents)

5. Saravanan Kappusamy (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Signpath Pharma, Inc.. Retrieved from https://idiyas.com/company/signpath-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…